Exhibit 99.2

img154328606_0.jpg

 

OCTOBER 28, 2026

 

GLAUKOS CORPORATION (NYSE: GKOS)

THIRD QUARTER 2026 IN REVIEW

Important Information

This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the “Additional Information” section of this document.

Conference Call Information

 

Date:

 

October 28, 2026

 

 

 

Time:

 

4:30 p.m. ET / 1:30 p.m. PT

 

 

 

Dial-in numbers:

 

1-833-461-5787 (U.S.), 1-585-542-9983 (International)

 

 

 

Confirmation ID:

 

517 868 366

 

 

 

Live webcast:

 

Events page at the Glaukos Investor Relations website at http://investors.glaukos.com or at this link.

 

 

 

Webcast replay:

 

A replay of the webcast will be archived on the Glaukos Investor Relations website following completion of the call.

 

img154328606_1.jpg

 

1


 

img154328606_2.jpg

OCTOBER 28, 2026

 

THIRD QUARTER 2026 FINANCIAL RESULTS SUMMARY

Business Description

Ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventional standard of care and improve outcomes for patients suffering from chronic eye diseases

Disease Categories

Glaucoma

Corneal Health

Retinal Disease

Revenue (Growth)

3Q 2026

$211.0 million

(+58% reported and constant currency versus 3Q 2025)

Gross Margin (Non-GAAP)

3Q 2026

~88%

(versus ~84% in 3Q 2025)

Operating Income (Non-GAAP)

3Q 2026

$27.3 million

(versus $9.3 million operating loss in 3Q 2025)

Net Income & EPS (Non-GAAP)

3Q 2026 Net Income

$28.5 million

(versus $9.2 million net loss in 3Q 2025)

3Q 2026 EPS

$0.47

(versus $0.16 EPS net loss in 3Q 2025)

Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash

$339.8 million as of September 30, 2026 (+$50.5 million versus $289.3 million as of June 30, 2026)

FY 2026 Sales Guidance

FY 2026 global consolidated revenues of $775 - $785 million expected

FY 2027 Preliminary Sales Guidance

FY 2027 global consolidated revenues of $1 billion expected

 

See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, and the other non-GAAP financial measures disclosed in this document to the most directly comparable GAAP financial measure are provided.

 

2


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Revenue Performance & Commercial Overview

 

Global Consolidated Revenue Performance

Glaukos reported record third quarter net revenues of $211.0 million that were up 58% on a reported and constant currency basis, versus 3Q 2025. Our third quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as growing contributions of Epioxa®.

 

img154328606_3.gif

 

Franchise Revenue Performance

 

img154328606_4.gif

 

3


 

img154328606_2.jpg

OCTOBER 28, 2026

 

 

U.S. Glaucoma

Our record third quarter U.S. Glaucoma net revenues were approximately $118.6 million, representing year-over-year growth of 47% versus 3Q 2025 driven by growing contributions from iDose TR, which generated sales of approximately $76 million in the third quarter.

During the third quarter, we successfully advanced execution of our commercialization of iDose TR, a first-of-its-kind intracameral procedural pharmaceutical that was designed to continuously deliver glaucoma drug therapy for up to three years. Most importantly, iDose TR continues to deliver strong clinical outcomes that meaningfully improve patients’ lives, resulting in strong physician interest and adoption while helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.

International Glaucoma

Our third quarter International Glaucoma net revenues were approximately $33.4 million, representing year-over-year growth of 13% on a reported basis, or 15% on a constant currency basis, versus 3Q 2025. The strong growth internationally during the third quarter was broad-based as we continue to scale our international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market in the world.

We remain in the early stages of expanding our IG and product portfolio initiatives globally ahead of anticipated new product approvals and expanding market access in the years to come.

Corneal Health

Our record third quarter Corneal Health net revenues were approximately $59.0 million, representing year-over-year growth of 154% versus 3Q 2025, including Epioxa net sales of approximately $53 million.

During the third quarter, we advanced our initial commercial launch plans for Epioxa, our novel, groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. We believe Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to reduce the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.

As the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, Epioxa has been met with strong interest from surgeons and the broader ophthalmic community, reinforcing our confidence in its potential to redefine the treatment paradigm for this rare, sight-threatening disease.

We will continue to focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.

 

4


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Additional Commercial Updates & Commentary

We have had several additional positive commercial updates worth highlighting here:

✓
Advanced commercial launch activities in the U.S. for iDose TR
o
Growing number of trained surgeons and accounts
o
Increasing utilization by the installed active surgeon base
o
Broadening and streamlining market access among MACs, commercial, and Medicare Advantage payers
o
Expanded set of peer-reviewed literature, now consisting of 27 different peer-reviewed publications highlighting iDose TR as a transformative new treatment alternative for patients suffering with glaucoma and ocular hypertension
o
Accelerating marketing investments to support increased patient awareness and education
✓
Advanced initial commercial launch plans for Epioxa
o
Epioxa commercial availability announced March 19, 2026
o
Successfully established, and continue to selectively expand, a broad-reaching site-of-care network, with acquired O2N systems already actively deployed at locations covering roughly 90% of the U.S. population, and a broader pipeline of systems moving through approval processes that would expand our treatment reach to more than 95%
o
Market access:
▪
Advancing efforts with payors to secure access pathways and policy coverage for Epioxa, with access pathways now established for approximately 90% of commercial lives in the U.S., including with the 5 largest payors, and more than 80% of Medicaid lives, reflecting encouraging receptivity of Epioxa’s clinical value
▪
We remain committed to securing access pathways with the remaining smaller and regional plans as we increasingly focus on pathway optimization and improving the time-to-treatment for patients
▪
Following the July 1, 2026 effective date of Epioxa’s product-specific J-code, J2789, we made encouraging progress during the third quarter in optimizing the operational processes supporting reporting and reimbursement. We remain focused on working

 

5


 

img154328606_2.jpg

OCTOBER 28, 2026

 

with providers and our specialty pharmacy partner to further refine these workflows and facilitate a more efficient and predictable reimbursement process for Epioxa.

 

 

o
Deployed various new patient services and support programs

img154328606_5.jpg

 

o
Launched Could it be KC? disease awareness and educational campaign in partnership with NBA champion Stephen Curry to raise awareness, educate patients and families, and promote earlier detection and diagnosis

 

o
Advancing targeted marketing and DTC campaigns designed to significantly enhance awareness, education, and detection, supported by greater optometric engagement and strengthened advocacy partnerships

 

o
Expanded new financial co-pay assistance program and operationalized Specialty Pharmacy partner network in support of Epioxa patients

 

✓
CMS’s Proposed Rules for Calendar Year 2027
o
Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedules: Proposed to maintain the 2026 APC assignments and largely maintain facility fee rates associated with our procedures across both the hospital outpatient and ASC settings.
o
Physician Fee Schedule (PFS) updates: Proposed modest reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including for cataract and surgical MIGS procedures specifically.

 

6


 

img154328606_2.jpg

OCTOBER 28, 2026

 

2026 Revenue Guidance Raised to Reflect Strong Momentum

Glaukos now expects full-year 2026 global consolidated net sales of $775 - $785 million, up from its previous guidance of $680 - $700 million. This guidance attempts to take into consideration:

•
Potential growing contributions from Epioxa as commercial launch plans advance and more streamlined access pathways are solidified operationally
•
Potential growing contributions from iDose TR as market access initiatives progress and broader IG initiatives take hold
•
Potential growing contributions from iStent infinite as broader IG initiatives take hold
•
Uncertainties associated with five MAC’s proposed LCDs for iDose TR
•
Combo-cataract MIGS competition globally
•
The continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives
•
The latest foreign currency exchange spot rates as of our 3Q 2026 earnings call on October 28, 2026
•
Global macroeconomic and geopolitical environment and associated uncertainties, which at this time are difficult to predict

 

7


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Research & Development / Pipeline Overview

Pipeline Summary

Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:

•
iStent® micro-scale surgical devices
•
iDose® sustained-release procedural pharmaceuticals
•
iLink® bio-activated pharmaceuticals
•
iLution™ transdermal pharmaceuticals
•
Retina XR bio-erodible sustained-release pharmaceuticals

 

img154328606_6.gif

 

 

8


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Key R&D and Pipeline Updates

We continue to advance a broad and differentiated clinical pipeline across our five novel therapeutic platforms, encompassing 14 publicly disclosed programs and additional undisclosed assets, supported by a robust portfolio of active clinical and Phase 4 studies. Recent updates in our pipeline include:

 

img154328606_7.jpg

iDose Platform Updates

 

✓
Announced U.S. FDA approval for NDA labeling supplement allowing for unlimited re-administration of iDose TR in patients who maintain a healthy cornea (January 2026)
✓
Advancing Phase 2b/3 clinical program for iDose TREX, our next-generation iDose therapy
o
Initial results of Phase 2a clinical trial demonstrated substantial IOP reductions of 8.6 to 10.8 mmHg through 3 months
✓
Advancing Phase 3b clinical program for iDose TRIO
o
Initial human factors study indicated strong user preference (~90% favorability)
✓
Announced positive topline results from our Phase 4 randomized controlled trial evaluating iDose TR in combination with cataract surgery (October 2026)
o
The study achieved its primary endpoint, demonstrating statistically significant superiority and a clinically meaningful IOP reduction compared to cataract surgery alone, with an 11.1 mmHg mean diurnal IOP reduction and a 3.6 mmHg incrementally superior treatment effect at 3 months
o
Favorable safety profile through three months
✓
Advancing various Phase 4 studies for iDose TR

 

9


 

 

Exhibit 99.2

img154328606_0.jpg

 

OCTOBER 28, 2026

 

 

 

img154328606_8.jpg

iLink Platform Updates

 

✓
Announced U.S. FDA approval for Epioxa (Epi-on) (October 2025)
o
Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated
o
Epioxa ushers in a new standard of care for patients
✓
Announced positive three-year extension study results for Epioxa, which demonstrated sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment (October 2026)
o
Treated eyes achieved a robust and sustained 1.9 diopter (D) improvement in maximum corneal curvature (Kmax) from baseline, reflecting meaningful long-term corneal flattening and stabilization
o
Treated eyes also demonstrated clinically meaningful visual outcomes at year 3, with 29% and 20% of eyes gaining two or more and three or more lines of best-corrected visual acuity from baseline, respectively
o
Favorable safety profile through 3 years
✓
Advancing development of KC screening device to support planned commercialization as we enter 2027
✓
Preparing to commence Phase 3 clinical program for third-generation, customized, tomography-guided iLink therapy in 2027
✓
Advancing Phase 2 clinical trial for iVeena

 

10


 

 

Exhibit 99.2

img154328606_0.jpg

 

OCTOBER 28, 2026

 

 

img154328606_9.jpg

iStent Platform Updates

 

✓
Completed patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients (4Q 2025)
✓
Announced EU MDR certification for iStent infinite (June 2025)
✓
Completed patient enrollment in 510(k) pivotal study for PRESERFLO™ MicroShunt (July 2026)

 

img154328606_10.jpg

iLution Platform Updates

 

✓
Completed enrollment in Phase 2 clinical trial for iLution™ Blepharitis (2Q 2026)

 

img154328606_11.jpg

Retina XR Platform Updates

 

✓
Announced exclusive license agreement with RevOpsis Therapeutics for RO-104, which was assigned Glaukos development code GLK-901, a first-in-class tri-specific biologic, as well as exclusive rights to the proprietary RevMod platform to discover and develop up to four additional next-generation multi-specific biologics for retinal diseases (October 2026)
✓
Completed patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401) (4Q 2025)

 

11


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Product / Pipeline Chart

 

img154328606_12.gif

 

 

12


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Other Financial Performance Overview

As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.

Third quarter 2026 financial performance summary:

 

 

img154328606_13.jpg

3Q 2026: 88%

3Q 2025: 84%

YoY ∆: +385 bps

•
Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro and Mobius acquisitions accounting

 

 

 

 

img154328606_14.jpg

3Q 2026: $109.7M

3Q 2025: $83.2M

YoY ∆: +32%

•
(-2%) sequential decrease vs $111.7M in 2Q 2026
•
YoY increase primarily reflects commercial and G&A investments globally and new product launch activities

 

 

 

 

img154328606_15.jpg

3Q 2026: $48.1M

3Q 2025: $38.1M

YoY ∆: +26%

•
(-6%) sequential decrease vs $51.3M in 2Q 2026
•
YoY increase primarily reflects continued investment in and advancement of R&D programs and clinical trials

 

 

 

 

img154328606_16.jpg

3Q 2026: $157.8M

3Q 2025: $121.3M

YoY ∆: +30%

•
(-3%) sequential decrease vs $163.0M in 2Q 2026

 

 

 

 

img154328606_17.jpg

 

 

 

 

 

 

 

Operating Income (Loss)

3Q 2026 $27.3M

3Q 2025: ($9.3M)

 

Net Income (Loss)

3Q 2026: $28.5M

3Q 2025: ($9.2M)

 

Diluted EPS (Loss)

3Q 2026: $0.47

3Q 2025: ($0.16)

 

 

 

 

 

img154328606_18.jpg

3Q 2026: $2.1M

3Q 2025: $1.6M

YoY ∆: +$0.5M

•
Capital expenditures reflect normal course spend primarily on business maintenance activities and equipment upgrades

 

 

 

 

img154328606_19.jpg

3Q 2026: $339.8M

2Q 2026: $289.3M

QoQ ∆: +$50.5M

 

 

 

 

 

 

 

 

13


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Other Important Updates

 

➢
While we believe our business is increasingly well positioned to deliver sustained cash generation and profitability as we scale, we remind investors that our primary focus remains on maximizing near- and long-term revenue growth and capitalizing on the significant opportunities in front of us. Accordingly, we remain committed to investing strategically across our industry-leading pipeline, commercial infrastructure, and market development initiatives to advance our innovation platforms, expand our addressable markets, and drive sustained top-line growth. We will continue to manage the business thoughtfully, balancing these strategic investments with disciplined expense management, capital allocation, and a focus on operational efficiency. Ultimately, we believe this approach best positions us to bring transformative therapies to patients, strengthen our financial profile, and drive sustainable, substantial long-term growth and shareholder value.
➢
Given the ongoing conversations around tariff and broader geopolitical volatility, we wanted to reiterate that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related policies. That said, the global tariff environment remains fluid, and more broadly, the current geopolitical backdrop and macroeconomic uncertainties continue to evolve. As such, we will continue to closely monitor these situations given the overall instability in the marketplace and global macroeconomic uncertainties.

 

14


 

img154328606_2.jpg

OCTOBER 28, 2026

 

 

img154328606_20.jpg

Additional Information

 

 

15


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Forward-Looking Statements

 

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to file on or before November 9, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or

 

16


 

img154328606_2.jpg

OCTOBER 28, 2026

 

clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

 

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. Beginning in the second quarter of 2022, we no longer exclude certain upfront and contingent milestone payments in connection with collaborative and licensing arrangements and certain in-process R&D charges for non-GAAP reporting and disclosure purposes.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Additional GAAP to Non-GAAP Reconciliations” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

 

17


 

img154328606_2.jpg

OCTOBER 28, 2026

 

GAAP Income Statement

 

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net sales

 

$

211,030

 

 

$

133,537

 

 

$

547,211

 

 

$

364,321

 

Cost of sales

 

 

31,164

 

 

 

28,831

 

 

 

98,519

 

 

 

80,043

 

Gross profit

 

 

179,866

 

 

 

104,706

 

 

 

448,692

 

 

 

284,278

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

130,943

 

 

 

82,999

 

 

 

339,946

 

 

 

237,047

 

Research and development

 

 

48,095

 

 

 

38,072

 

 

 

143,541

 

 

 

106,963

 

Acquired in-process research and development

 

 

-

 

 

 

-

 

 

 

1,500

 

 

 

-

 

Total operating expenses

 

 

179,038

 

 

 

121,071

 

 

 

484,987

 

 

 

344,010

 

Income (loss) from operations

 

 

828

 

 

 

(16,365

)

 

 

(36,295

)

 

 

(59,732

)

Non-operating income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

2,493

 

 

 

2,552

 

 

 

7,203

 

 

 

8,202

 

Interest expense

 

 

(1,087

)

 

 

(1,175

)

 

 

(3,671

)

 

 

(3,489

)

Other income (expense), net

 

 

87

 

 

 

(1,009

)

 

 

(1,936

)

 

 

1,793

 

Total non-operating income

 

 

1,493

 

 

 

368

 

 

 

1,596

 

 

 

6,506

 

Income (loss) before taxes

 

 

2,321

 

 

 

(15,997

)

 

 

(34,699

)

 

 

(53,226

)

Income tax provision

 

 

303

 

 

 

234

 

 

 

1,443

 

 

 

808

 

Net income (loss)

 

$

2,018

 

 

$

(16,231

)

 

$

(36,142

)

 

$

(54,034

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income (loss) per share

 

$

0.03

 

 

$

(0.28

)

 

$

(0.62

)

 

$

(0.95

)

Diluted net income (loss) per share

 

$

0.03

 

 

$

(0.28

)

 

$

(0.62

)

 

$

(0.95

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding used to compute
    basic net income (loss) per share

 

 

59,105

 

 

 

57,398

 

 

 

58,651

 

 

 

57,083

 

Weighted-average shares outstanding used to compute
    diluted net income (loss) per share

 

 

61,196

 

 

 

57,398

 

 

 

58,651

 

 

 

57,083

 

 

 

18


 

img154328606_2.jpg

OCTOBER 28, 2026

 

GAAP Balance Sheet

 

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

162,327

 

 

$

90,813

 

Short-term investments

 

 

174,372

 

 

 

187,947

 

Accounts receivable, net

 

 

150,004

 

 

 

108,608

 

Inventory

 

 

61,032

 

 

 

63,564

 

Prepaid expenses and other current assets

 

 

31,915

 

 

 

24,052

 

Total current assets

 

 

579,650

 

 

 

474,984

 

Restricted cash

 

 

3,115

 

 

 

3,834

 

Property and equipment, net

 

 

112,068

 

 

 

113,253

 

Operating lease right-of-use asset

 

 

30,795

 

 

 

31,527

 

Finance lease right-of-use asset

 

 

37,594

 

 

 

39,404

 

Intangible assets, net

 

 

121,261

 

 

 

141,916

 

Goodwill

 

 

66,710

 

 

 

66,710

 

Deposits and other assets

 

 

28,336

 

 

 

21,859

 

Total assets

 

$

979,529

 

 

$

893,487

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

24,407

 

 

$

24,624

 

Accrued liabilities

 

 

102,319

 

 

 

76,651

 

Total current liabilities

 

 

126,726

 

 

 

101,275

 

Operating lease liability

 

 

35,057

 

 

 

35,767

 

Finance lease liability

 

 

66,926

 

 

 

68,109

 

Deferred tax liability, net

 

 

441

 

 

 

441

 

Other liabilities

 

 

33,105

 

 

 

31,740

 

Total liabilities

 

 

262,255

 

 

 

237,332

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000 shares authorized; no
   shares issued and outstanding as of September 30, 2026 and
   December 31, 2025

 

 

-

 

 

 

-

 

Common stock, $0.001 par value; 150,000 shares authorized; 59,196
   and 57,539 shares issued and 59,168 and 57,511 shares
   outstanding at September 30, 2026 and December 31, 2025, respectively

 

 

59

 

 

 

58

 

Additional paid-in capital

 

 

1,684,829

 

 

 

1,586,056

 

Accumulated other comprehensive income

 

 

1,790

 

 

 

3,303

 

Accumulated deficit

 

 

(969,272

)

 

 

(933,130

)

Less treasury stock (28 shares as of September 30, 2026 and December 31,
   2025)

 

 

(132

)

 

 

(132

)

Total stockholders' equity

 

 

717,274

 

 

 

656,155

 

Total liabilities and stockholders' equity

 

$

979,529

 

 

$

893,487

 

 

 

19


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Primary GAAP to Non-GAAP Reconciliations

 

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

 

 

 

Q3 2026

 

 

Q3 2025

 

 

 

GAAP

 

 

Adjustments

 

 

Non-GAAP

 

 

GAAP

 

 

Adjustments

 

 

Non-GAAP

 

Cost of sales

 

$

31,164

 

 

$

(5,274

)

(A)

$

25,890

 

 

$

28,831

 

 

$

(7,310

)

(A)(B)

$

21,521

 

Gross Margin

 

 

85.2

%

 

 

2.5

%

 

 

87.7

%

 

 

78.4

%

 

 

5.5

%

 

 

83.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

$

130,943

 

 

$

(21,219

)

(C)(D)

$

109,724

 

 

$

82,999

 

 

$

243

 

(D)

$

83,242

 

Income (loss) from operations

 

$

828

 

 

$

26,493

 

 

$

27,321

 

 

$

(16,365

)

 

$

7,067

 

 

$

(9,298

)

Net income (loss)

 

$

2,018

 

 

$

26,493

 

(E)

$

28,511

 

 

$

(16,231

)

 

$

7,067

 

(E)

$

(9,164

)

Basic net income (loss) per share

 

$

0.03

 

 

$

0.45

 

 

$

0.48

 

 

$

(0.28

)

 

$

0.12

 

 

$

(0.16

)

Diluted net income (loss) per share

 

$

0.03

 

 

$

0.44

 

 

$

0.47

 

 

$

(0.28

)

 

$

0.12

 

 

$

(0.16

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares
   outstanding used to
   compute basic net income
   (loss) per share

 

 

59,105

 

 

 

 

 

 

59,105

 

 

 

57,398

 

 

 

 

 

 

57,398

 

Weighted-average shares
   outstanding used to
   compute diluted net income
   (loss) per share

 

 

61,196

 

 

 

 

 

 

61,196

 

 

 

57,398

 

 

 

 

 

 

57,398

 

 

(A)

•
Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $4.8 million in Q3 2026 and $5.5 million in Q3 2025.
•
Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million in Q3 2026 and Q3 2025, respectively.

(B)

•
Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•
Expenses of $5.9 million related to the Company’s trade secrets litigation and other litigation matters.
•
Expense of $14.1 million related to the resolution agreement with the Regents of the University of California.
•
Expenses of $0.8 million associated with the integration of a major system.

(D)

•
Mobius contingent consideration fair value adjustments of $0.4 million in Q3 2026 and ($0.2) million in Q3 2025.

(E)

•
Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

 

20


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Primary GAAP to Non-GAAP Reconciliations

 

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

 

 

 

Year-to-Date Q3 2026

 

 

Year-to-Date Q3 2025

 

 

 

GAAP

 

 

Adjustments

 

 

Non-GAAP

 

 

GAAP

 

 

Adjustments

 

 

Non-GAAP

 

Cost of sales

 

$

98,519

 

 

$

(19,222

)

(A)

$

79,297

 

 

$

80,043

 

 

$

(18,597

)

(A)(B)

$

61,446

 

Gross Margin

 

 

82.0

%

 

 

3.5

%

 

 

85.5

%

 

 

78.0

%

 

 

5.1

%

 

 

83.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

$

339,946

 

 

$

(26,316

)

(C)(D)

$

313,630

 

 

$

237,047

 

 

$

(52

)

(D)

$

236,995

 

(Loss) income from operations

 

$

(36,295

)

 

$

45,538

 

 

$

9,243

 

 

$

(59,732

)

 

$

18,649

 

 

$

(41,083

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-operating income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

$

(3,671

)

 

$

369

 

(E)

$

(3,302

)

 

$

(3,489

)

 

$

-

 

 

$

(3,489

)

Net (loss) income

 

$

(36,142

)

 

$

45,907

 

(F)

$

9,765

 

 

$

(54,034

)

 

$

18,649

 

(F)

$

(35,385

)

Basic net (loss) income per share

 

$

(0.62

)

 

$

0.79

 

 

$

0.17

 

 

$

(0.95

)

 

$

0.33

 

 

$

(0.62

)

Diluted net (loss) income per share

 

$

(0.62

)

 

$

0.78

 

 

$

0.16

 

 

$

(0.95

)

 

$

0.33

 

 

$

(0.62

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares
   outstanding used to
   compute basic net income
   (loss) per share

 

 

58,651

 

 

 

 

 

 

58,651

 

 

 

57,083

 

 

 

 

 

 

57,083

 

Weighted-average shares
   outstanding used to
   compute diluted net income
   (loss) per share (G)

 

 

58,651

 

 

 

 

 

 

60,598

 

 

 

57,083

 

 

 

 

 

 

57,083

 

 

(A)

•
Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $17.8 million year-to-date Q3 2026 and $16.6 million year-to-date Q3 2025.
•
Mobius acquisition-related amortization expense of developed intellectual property of $1.5 million year-to-date Q3 2026 and $0.7 million year-to-date Q3 2025.

(B)

•
Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million.

(C)

•
Expenses of $9.9 million related to the Company’s trade secrets litigation and other litigation matters.
•
Expense of $14.1 million related to the resolution agreement with the Regents of the University of California.
•
Expenses of $1.2 million associated with the integration of a major system.
•
Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(D)

•
Mobius contingent consideration fair value adjustments of $0.4 million year-to-date Q3 2026 and ($0.2) million year-to-date Q3 2025.
•
Mobius acquisition-related transaction expense of $0.3 million year-to-date Q3 2025.

(E)

•
Interest expense related to the untimely payment of prior period payroll withholdings.

(F)

•
Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

(G)

•
Year-to-date Q3 2026 non-GAAP diluted weighted-average shares reflect the dilution effect from outstanding stock options, unvested restricted stock units, performance-based equity awards, and employee stock purchase program option shares under the treasury stock method.

 

21


 

img154328606_2.jpg

OCTOBER 28, 2026

 

Additional GAAP to Non-GAAP Reconciliations

 

 

Reported Sales vs. Prior Periods (in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Year-over-Year Percent Change

 

 

Quarter-over-Quarter Percent Change

 

 

 

3Q 2026

 

 

3Q 2025

 

 

2Q 2026

 

 

Reported

 

 

Operations (1)

 

 

Currency (2)

 

 

Reported

 

 

Operations (1)

 

 

Currency (2)

 

International
   Glaucoma

 

$

33,356

 

 

$

29,443

 

 

$

36,631

 

 

 

13.3

%

 

 

14.6

%

 

 

(1.3

%)

 

 

(8.9

%)

 

 

(8.4

%)

 

 

(0.5

%)

Total Net Sales

 

$

211,030

 

 

$

133,537

 

 

$

185,610

 

 

 

58.0

%

 

 

58.3

%

 

 

(0.3

%)

 

 

13.7

%

 

 

13.8

%

 

 

(0.1

%)

 

(1) Operational growth excludes the effect of translational currency

(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

For Non-GAAP disclosures associated with the company’s past quarterly results, included with respect to the sequential comparisons included herein, please see reconciliations here.

 

22